Shattuck Labs Inc (STTK) - Total Liabilities
Based on the latest financial reports, Shattuck Labs Inc (STTK) has total liabilities worth $7.09 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shattuck Labs Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Shattuck Labs Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Shattuck Labs Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Shattuck Labs Inc Competitors by Total Liabilities
The table below lists competitors of Shattuck Labs Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jack In The Box Inc
NASDAQ:JACK
|
USA | $3.53 Billion |
|
Genfit S.A.
NASDAQ:GNFT
|
USA | $164.21 Million |
|
Sino AG
F:XTP
|
Germany | €2.38 Million |
|
Wuhan Golden Laser Co Ltd
SHE:300220
|
China | CN¥220.56 Million |
|
AC Immune Ltd
NASDAQ:ACIU
|
USA | $105.89 Million |
|
Pihlajalinna Oy
HE:PIHLIS
|
Finland | €407.30 Million |
|
Pioneer High Income Closed Fund
NYSE:PHT
|
USA | $116.53 Million |
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
USA | $16.49 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Shattuck Labs Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shattuck Labs Inc (STTK) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shattuck Labs Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shattuck Labs Inc (2018–2024)
The table below shows the annual total liabilities of Shattuck Labs Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.42 Million | -23.12% |
| 2023-12-31 | $14.86 Million | -49.06% |
| 2022-12-31 | $29.17 Million | +8.84% |
| 2021-12-31 | $26.80 Million | -31.51% |
| 2020-12-31 | $39.13 Million | -50.79% |
| 2019-12-31 | $79.52 Million | +0.35% |
| 2018-12-31 | $79.24 Million | -- |
About Shattuck Labs Inc
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inf… Read more